Drug Type CRISPR/Cas9 |
Synonyms- |
Target |
Mechanism PTBP1 inhibitors(polypyrimidine tract binding protein 1 inhibitors), ROCK modulators(Rho-associated kinases modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Preclinical | CN | 23 Apr 2024 |